ComplianceOnline

483 sent to Jilin Shulan Synthetic Pharmaceutical Co.

  • By: Staff Editor
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

Warning letter sent to Jilin Shulan Synthetic Pharmaceutical Co. regarding significant deviations from Current Good Manufacturing Practice (CGMP) for the manufacture of APIs.

Bookmark and Share

Trending Compliance Trainings

Challenges of an Effective Change Control Program
By - Kenneth Christie
On Demand Access Anytime
Implementation and Management of GMP Data Integrity
By - Danielle DeLucy
On Demand Access Anytime
FDA Compliance and Clinical Trial Computer System Validation
By - Carolyn Troiano
On Demand Access Anytime
Biocompatibility Testing; what you need to know
By - Mike Colvin
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading